These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 17914897

  • 1. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J, Bramlage P, Lüders S, Thoenes M, Schirmer A, Paar DW.
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V, Boccanelli A, Ewald S, Girerd X, Heagerty A, Krzesinski JM, Lins R, Rodicio J, Stefenelli T, Woittiez A, Böhm M.
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ, Weir MR.
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [Abstract] [Full Text] [Related]

  • 4. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG, Neutel JM, Ferdinand KC, INCLUSIVE investigators.
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
    Napoli C, Omboni S, Borghi C, ZAMES (Zofenopril in Advanced MEtabolic Syndrome) Study Group.
    J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A, Calvo C, Sobrino J, Gómez E, López-Paz JE, Sierra C, Bragulat E, de la Sierra A.
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [Abstract] [Full Text] [Related]

  • 15. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
    Agabiti-Rosei E, Manolis A, Zava D, Omboni S, ZODIAC Study Group.
    Adv Ther; 2014 Feb; 31(2):217-33. PubMed ID: 24415271
    [Abstract] [Full Text] [Related]

  • 16. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F, Bramlage P, Paar WD.
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
    Al Balushi KA, Habib JQ, Al-Zakwani I.
    Med Princ Pract; 2013 Sep; 22(3):265-9. PubMed ID: 23235349
    [Abstract] [Full Text] [Related]

  • 18. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.
    Franklin S, Lapuerta P, Cox D, Donovan M.
    J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):15-22. PubMed ID: 18046108
    [Abstract] [Full Text] [Related]

  • 19. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 20. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.
    Schmieder RE, Schwertfeger M, Bramlage P.
    Vasc Health Risk Manag; 2009 Jan; 5():991-1000. PubMed ID: 19997579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.